Bio-Thera Solutions and Dr. Reddy’s Laboratories SA announced that they had entered into commercialization and licensing agreements ...

The European Commission (EC) has approved ustekinumab for the treatment of moderately to severely active Crohn’s disease in ...

The use of 5-aminosalicylic acid with ustekinumab shows no significant overall benefits in inflammatory bowel disease. However, post hoc subgroup analyses suggest potential benefits in specific ...

The clinical results demonstrated that STEQEYMA and its reference product, ustekinumab, are highly similar, and have no clinically meaningful differences in terms of safety and efficacy.

If you've ever tried discussing medicines with friends or family and found yourself stumbling over the pronunciation - or ...

SAN FRANCISCO -- Research presented at the annual Crohn's and Colitis Congress included studies comparing the effectiveness of vedolizumab (Entyvio) versus ustekinumab (Stelara) and of each ...

In a retrospective cohort study, ustekinumab and guselkumab show trends toward lower risk for herpes zoster in patients with ...

--(BUSINESS WIRE)--Fresenius Kabi, an operating company of Fresenius, and Formycon AG, a leading, independent developer of high-quality biosimilars, announced today that the ustekinumab biosimilar ...

STEQEYMA® (ustekinumab-stba) is Celltrion's biosimilar to STELARA® (ustekinumab), which was launched on March 12, 2025 ...